Squamous Cell Lung Cancer

An incidental lung nodule program detected early-stage lung cancer with higher frequency than most low-dose CT programs, according to a poster presented at the virtual 2021 ASCO Annual Meeting.

As medicine as a whole reexamines the racism – implicit and explicit – within the structure of treatment and the health care system, the resulting disparities exist as focal points for all specialties, lung cancer not withstanding.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, highlighted updated data in squamous cell lung cancer and mesothelioma presented at the Chemotherapy Foundation Symposium.

The FDA granted priority review to atezolizumab monotherapy as first-line treatment for patients with advanced nonsquamous or squamous non-small cell lung cancer without EGFR or ALK mutations and with high PD-L1 expression, according to a press release from the agent’s manufacturer.

Atezolizumab as first-line monotherapy prolonged OS compared with chemotherapy alone for certain patients with non-small cell lung cancer, according to the agent’s manufacturer.